HC Wainwright Analysts Boost Earnings Estimates for COYA

Coya Therapeutics, Inc. (NASDAQ:COYA) – Equities researchers at HC Wainwright boosted their Q1 2026 earnings per share estimates for shares of Coya Therapeutics in a research note issued to investors on Monday, February 2nd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.33) per share for the quarter, up from their previous estimate of ($0.37). HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.46) EPS and FY2026 earnings at ($1.52) EPS.

Other analysts have also recently issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Wednesday, January 21st. BTIG Research lifted their price target on shares of Coya Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Lake Street Capital reissued a “buy” rating and set a $17.00 price objective on shares of Coya Therapeutics in a research note on Wednesday, November 5th. Chardan Capital restated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a report on Thursday, January 8th. Finally, D. Boral Capital reiterated a “buy” rating and set a $15.00 target price on shares of Coya Therapeutics in a report on Wednesday, January 21st. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Coya Therapeutics Stock Up 2.5%

Shares of COYA stock opened at $4.86 on Wednesday. The business’s fifty day moving average is $5.36 and its 200 day moving average is $5.88. The stock has a market cap of $101.67 million, a price-to-earnings ratio of -4.38 and a beta of 0.27. Coya Therapeutics has a twelve month low of $3.94 and a twelve month high of $8.29.

Coya Therapeutics (NASDAQ:COYA) last announced its earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.12). Coya Therapeutics had a negative return on equity of 55.76% and a negative net margin of 462.24%.The firm had revenue of $3.56 million during the quarter, compared to the consensus estimate of $3.70 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. CM Management LLC grew its holdings in shares of Coya Therapeutics by 16.7% during the fourth quarter. CM Management LLC now owns 350,000 shares of the company’s stock valued at $2,030,000 after buying an additional 50,000 shares during the last quarter. Dauntless Investment Group LLC lifted its position in Coya Therapeutics by 199.5% in the 3rd quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock valued at $872,000 after acquiring an additional 101,932 shares in the last quarter. Citadel Advisors LLC lifted its position in Coya Therapeutics by 51.3% in the 3rd quarter. Citadel Advisors LLC now owns 65,240 shares of the company’s stock valued at $372,000 after acquiring an additional 22,120 shares in the last quarter. Jane Street Group LLC boosted its stake in Coya Therapeutics by 101.7% during the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock valued at $169,000 after purchasing an additional 13,176 shares during the last quarter. Finally, Prosperity Wealth Management Inc. increased its holdings in shares of Coya Therapeutics by 16.4% in the 3rd quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock worth $136,000 after purchasing an additional 3,350 shares in the last quarter. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.